AndroGel Vaccine Interaction Profile: What Every Patient and Clinician Needs to Know

Does AndroGel Interact With Vaccines?

No vaccine currently listed on the CDC adult immunization schedule has a pharmacokinetic interaction with testosterone gel. The FDA-approved prescribing information for AndroGel lists no vaccines under contraindications or drug interactions. Vaccine-preventable disease risk in hypogonadal men is, if anything, elevated because testosterone deficiency itself correlates with poorer metabolic health.

What the FDA Label Actually Says

The AndroGel 1.62% prescribing label (NDA 202763) identifies three interaction categories: oral anticoagulants, insulin, and ACTH or corticosteroids. Vaccines appear in none of those categories. The label does warn about skin-to-skin transfer of testosterone to other individuals, which is relevant when a nurse or pharmacist administers an injection. The solution is simple: cover the AndroGel application site with clothing before any clinical contact. [1]

Testosterone, the Immune System, and Vaccines

Testosterone receptors are expressed on T cells, B cells, and macrophages. A 2021 review in Frontiers in Immunology confirmed that physiologic androgen concentrations suppress pro-inflammatory cytokines (IL-6, TNF-alpha) and modestly reduce Th1-driven antibody class switching. [2] This biological plausibility has prompted researchers to ask whether men on testosterone replacement therapy (TRT) produce weaker vaccine responses.

The short answer from the available data: antibody titers may be slightly lower in men with high testosterone, but seroprotection rates remain above the thresholds considered clinically protective. A 2022 analysis of COVID-19 vaccine immunogenicity published in JAMA Network Open found that male sex (associated with higher androgen levels) was not a predictor of vaccine failure or hospitalization after two-dose mRNA vaccination. [3]

CDC and ACIP Guidance for Men on TRT

The CDC Advisory Committee on Immunization Practices (ACIP) does not list testosterone replacement as a condition requiring a modified vaccine schedule. The 2024 CDC adult immunization schedule recommends influenza annually, COVID-19 updated formulation annually, Tdap once then Td every 10 years, and age-appropriate pneumococcal, shingles (RZV), and RSV vaccines, all without exceptions for men on androgen therapy. [4]

Immunogenicity Evidence: What Clinical Studies Show

Influenza Vaccine and Testosterone

A prospective cohort study by Engler et al. Examined sex-based differences in influenza vaccine responses and found that men, as a group, produced lower hemagglutination inhibition (HAI) titers than women. A 2008 paper in Vaccine (PMID 18054441) reported that testosterone levels correlated inversely with antibody magnitude in a mixed-sex sample. [5] The clinical implication is not to skip the flu shot. Men on TRT should receive it on the standard annual schedule.

COVID-19 mRNA Vaccines and Androgen Signaling

TMPRSS2, a cell-surface protease that primes SARS-CoV-2 spike protein for entry, is androgen-regulated. Higher androgen activity upregulates TMPRSS2 expression in lung epithelium. This raised early concern that TRT might worsen COVID-19 susceptibility or blunt mRNA vaccine efficacy. A 2021 observational study in The Journal of Clinical Endocrinology and Metabolism (N=723 men, PMID 34255060) found that testosterone levels at the time of COVID-19 diagnosis were inversely associated with disease severity. Low testosterone, not high testosterone, predicted ICU admission. [6]

Vaccine efficacy data from the BNT162b2 (Pfizer-BioNTech) and mRNA-1273 (Moderna) trials were not stratified by exogenous androgen use. No signal of reduced protection in TRT users emerged from post-authorization safety surveillance reported to VAERS or from VA health system analyses. [7]

HPV, Hepatitis B, and Other Adjuvanted Vaccines

Hepatitis B surface antibody (anti-HBs) titers above 10 mIU/mL define seroprotection. A study in Vaccine (PMID 16337719) noted that male sex was a predictor of non-response to hepatitis B vaccination, with approximately 5-10% of healthy adult males failing to reach protective titers after three doses. [8] Whether this reflects testosterone specifically or broader sex-linked immunological differences is not resolved. Men on TRT who are hepatitis B non-immune should follow the standard three-dose series and have anti-HBs checked 1-2 months after the final dose, as recommended by the ACIP hepatitis B guidelines. [9]

HPV vaccination (Gardasil 9) is now recommended by ACIP through age 26 for all adults, and shared clinical decision-making up to age 45. No testosterone-specific interaction data exists for HPV vaccine. Gardasil 9 is an aluminum-adjuvanted subunit vaccine; testosterone does not alter aluminum adjuvant processing in a clinically meaningful way based on current evidence. [10]

AndroGel and Alcohol: The Absorption Question

How Ethanol Affects Transdermal Testosterone Delivery

AndroGel is formulated in an ethanol-based gel carrier. The gel itself already contains 67.0% ethanol by weight (per the 1% formulation label), which is why it must not be applied near open flames. Drinking alcohol does not add ethanol to the application site, but systemic ethanol causes peripheral vasodilation that can transiently increase dermal blood flow and alter transdermal drug absorption kinetics. A 2004 pharmacokinetic study in Clinical Pharmacokinetics (PMID 15153153) documented that alcohol-induced cutaneous vasodilation increases transdermal permeation rates for lipophilic compounds by up to 30% in some models. [11]

Chronic Alcohol Use and Testosterone Levels

The more clinically significant alcohol-AndroGel relationship is chronic: heavy alcohol use suppresses hypothalamic GnRH pulsatility, reducing endogenous LH and FSH, and directly impairs Leydig cell testosterone synthesis. Men who drink more than 14 standard drinks per week may have lower trough testosterone despite adequate dosing, not from any pharmacokinetic interaction, but because alcohol-induced liver disease reduces sex hormone-binding globulin (SHBG) in a variable way that complicates free testosterone interpretation. A 2014 review in Alcohol (PMID 24041916) summarized the hypothalamic-pituitary-gonadal suppression seen with chronic ethanol exposure. [12]

Patients on AndroGel who drink heavily should have total and free testosterone, LH, and SHBG checked together at follow-up, not testosterone alone.

Full AndroGel Drug Interaction Profile

The table below organizes AndroGel interactions by mechanism and clinical severity. This framework was developed by the HealthRX clinical team to give prescribers a single-reference decision aid not available in compiled form on the FDA label.

Anticoagulants: The Highest-Risk Interaction

Testosterone potentiates the anticoagulant effect of warfarin. The mechanism is two-fold: testosterone inhibits CYP2C9-mediated warfarin metabolism, raising plasma warfarin concentrations, and androgens independently suppress synthesis of vitamin K-dependent clotting factors II, V, VII, and X. The AndroGel 1.62% FDA label states: "Changes in anticoagulant activity may be seen with androgens, therefore more frequent monitoring of international normalized ratio (INR) and prothrombin time are recommended in patients taking anticoagulants, especially at the initiation and termination of androgen therapy." [1]

INR should be checked within 2 weeks of starting, stopping, or dose-adjusting AndroGel in any patient on warfarin. Direct oral anticoagulants (DOACs: apixaban, rivaroxaban, edoxaban, dabigatran) are not metabolized by CYP2C9, so this specific enzyme interaction does not apply, but bleeding risk monitoring remains prudent. [13]

Insulin and Oral Hypoglycemics

Testosterone improves insulin sensitivity through multiple pathways including increased lean body mass, reduced visceral adiposity, and upregulation of GLUT4 expression. The clinical result: men initiating TRT who take insulin or sulfonylureas may experience hypoglycemia as insulin requirements fall. A 2016 Cochrane systematic review (CD010207) covering 39 trials found that testosterone therapy in men with type 2 diabetes reduced HbA1c by a mean of 0.87% and fasting glucose by 1.35 mmol/L compared to placebo. [14] Glucose monitoring should be intensified in the first 4-6 weeks after TRT initiation.

Corticosteroids and ACTH

Concurrent use of corticosteroids and androgens increases the risk of edema, particularly in patients with pre-existing cardiac or hepatic disease. The FDA label specifically flags this pairing. [1] Fluid retention from this combination may worsen hypertension or heart failure. Prednisone doses above 10 mg/day for more than 2 weeks merit close blood pressure and weight monitoring in AndroGel users.

Medications With Limited or No Interaction

• Statins: No pharmacokinetic interaction. Testosterone does not meaningfully alter CYP3A4 activity at therapeutic doses.
• ACE inhibitors / ARBs: No interaction. Both drug classes are commonly co-prescribed in men with metabolic syndrome on TRT.
• SSRIs/SNRIs: No pharmacokinetic interaction. Some men experience improved mood and libido on TRT that may reduce SSRI reliance, but this is a pharmacodynamic effect, not a drug interaction in the traditional sense.
• PDE5 inhibitors (sildenafil, tadalafil): No pharmacokinetic interaction. Testosterone and PDE5 inhibitors are often co-prescribed because hypogonadism blunts PDE5 inhibitor efficacy; correcting testosterone first sometimes restores response. A 2004 study in European Urology (PMID 15474267) found that sildenafil non-responders with low testosterone improved significantly after TRT was added. [15]

Practical Administration Guidance for Vaccine Visits

Preventing Testosterone Transfer During Injection

AndroGel application sites include the upper arms, shoulders, and abdomen. Standard intramuscular and subcutaneous vaccine injection sites include the deltoid (upper arm) and anterolateral thigh. If the patient applies AndroGel to the shoulder or upper arm and then receives a deltoid injection, residual gel on the skin could theoretically contact the healthcare worker's gloved hand.

The FDA label requires AndroGel to be washed off before skin-to-skin contact. The practical protocol for vaccine visits:

1. Apply AndroGel at the usual morning time.
2. Allow 5 minutes for gel drying (standard label instruction).
3. Wear a shirt to the appointment. The clothing barrier prevents gel transfer.
4. Inform the administering clinician that the arm or shoulder is an AndroGel application site so they can choose the contralateral arm or the thigh if preferred.

Timing AndroGel Around Vaccination Day

No pharmacological reason exists to skip, delay, or double AndroGel doses on vaccination day. Serum testosterone peaks 2 hours after application and returns toward trough over 24 hours. This diurnal variation does not interact with vaccine antigen processing, adjuvant function, or the development of germinal center B-cell responses, which unfold over days to weeks. [16]

A post-vaccination injection-site reaction (redness, swelling, tenderness) is not related to AndroGel unless the vaccine was injected directly into an AndroGel-covered area that was not cleaned first. Clean the injection site with an alcohol swab regardless.

Special Populations: What the Evidence Supports

Older Men (Age 65 and Above)

Immunosenescence, the age-related decline in vaccine responsiveness, is well documented. A 2015 CDC MMWR report noted that influenza vaccine effectiveness in adults 65 and older averages 40-60%, compared to 50-70% in younger adults. [17] Testosterone levels also decline with age (roughly 1-2% per year after age 30). In older men on TRT, the net effect on vaccine immunogenicity is unlikely to be clinically different from age-matched men not on TRT, because both groups have similar androgen exposures. High-dose influenza vaccine (Fluzone High-Dose) or adjuvanted formulations (FLUAD) are preferred in this age group per ACIP 2024 guidance, irrespective of TRT status.

Men With Autoimmune Conditions

Testosterone's immunosuppressive properties raise a theoretical concern: could TRT blunt vaccine efficacy in men with autoimmune diseases who are already on immunomodulatory therapy? The data here are sparse. Men on rituximab, mycophenolate, or high-dose steroids have attenuated vaccine responses, but this is driven by those medications, not by testosterone. A 2022 ACR guidance statement recommended that rheumatology patients time vaccinations to periods of lowest immunosuppression, which applies to their disease-modifying drugs, not to TRT. [18]

Prostate Cancer Survivors

Men with a history of prostate cancer who are on androgen deprivation therapy (ADT) represent the pharmacological inverse of TRT users. ADT suppresses testosterone to castrate levels. ADT-induced immune changes include a shift toward Th2 cytokine profiles. A 2020 analysis in European Urology (PMID 32029355) found that ADT use was associated with more severe COVID-19 outcomes, consistent with the finding that low testosterone, not high testosterone, correlates with poorer immune defense. [19] These men are not AndroGel candidates, but their data reinforce the point that testosterone replacement does not suppress clinically meaningful vaccine immunity.

Monitoring Parameters for Men on AndroGel

Routine monitoring on AndroGel does not change because of vaccination. Standard follow-up includes:

• Serum testosterone (total, morning draw, 2 hours after application): target 400-700 ng/dL per most guidelines, checked at 3-6 months after initiation and annually once stable. The Endocrine Society 2018 Clinical Practice Guideline recommends maintaining testosterone in the mid-normal range (400-700 ng/dL). [20]
• Hematocrit: checked at 3 months, 6 months, then annually. Testosterone stimulates erythropoiesis; hematocrit above 54% warrants dose reduction or phlebotomy.
• PSA: baseline and at 3-6 months in men over 40, then annually.
• Lipid panel: annually; testosterone modestly reduces HDL in some men.
• INR: within 2 weeks of any dose change in men on warfarin. [1]